Related Experiment Video
Updated: Mar 31, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Advances in small-molecule drug discovery for triple-negative breast cancer
Nelly Fosu-Mensah1, María Sánchez Peris1, Hoi Ping Weeks2
1School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, UK.
Abstract:
Triple-negative breast cancer (TNBC) is a subtype of poor prognosis, highly invasive and difficult-to-treat breast cancers accounting for approximately 15% of clinical cases. Given the poor outlook and lack of sustained response to conventional therapies, TNBC has been the subject of intense studies on new therapeutic approaches in recent years. The development of targeted cancer therapies, often in combination with established chemotherapy, has been applied to a number of new clinical studies in this setting in recent years. This review will highlight recent therapeutic advances in TNBC, focusing on small-molecule drugs and their associated biological mechanisms of action, and offering the possibility of improved prospects for this patient group in the near future.
Insights
Triple-negative breast cancer (TNBC) is aggressive and hard to treat. Recent research focuses on targeted therapies and small-molecule drugs to improve treatment outcomes for TNBC patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) represents a significant clinical challenge due to its aggressive nature and poor prognosis.
- Approximately 15% of breast cancer cases are diagnosed as TNBC, often exhibiting high invasiveness and resistance to standard treatments.
Purpose of the Study:
- To review recent therapeutic advancements in treating triple-negative breast cancer.
- To focus on the mechanisms of action of novel small-molecule drugs and targeted therapies.
Main Methods:
- Literature review of recent clinical studies and research on TNBC therapies.
- Analysis of small-molecule drugs and targeted agents in preclinical and clinical settings.
Main Results:
- Emerging targeted therapies, including small-molecule drugs, show promise in overcoming TNBC's resistance to conventional chemotherapy.
- Combination strategies involving novel agents alongside chemotherapy are being explored in ongoing clinical trials.
Conclusions:
- Recent therapeutic advances offer potential for improved outcomes in triple-negative breast cancer.
- Targeted small-molecule drugs represent a promising avenue for future TNBC treatment strategies.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies